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Abstract
Background Health economic evaluations of interventions in infectious disease are com-
monly based on the predictions of ordinary differential equation (ODE) systems or Markov
models (MMs). Standard MMs are static, whereas ODE systems are usually dynamic and
account for herd immunity which is crucial to prevent overestimation of infection prevalence.
Complex ODE systems including distributions on model parameters are computationally in-
tensive. Thus, mainly ODE-based models including fixed parameter values are presented in
the literature. These do not account for parameter uncertainty. As a consequence, probabilis-
tic sensitivity analysis (PSA), a crucial component of health economic evaluations, cannot
be conducted straightforwardly.
Methods We present a dynamic MM under a Bayesian framework. We extend a static
MM by incorporating the force of infection into the state allocation algorithm. The cor-
responding output is based on dynamic changes in prevalence and thus accounts for herd
immunity. In contrast to deterministic ODE-based models, PSA can be conducted straight-
forwardly. We introduce a case study of a fictional sexually transmitted infection and com-
pare our dynamic Bayesian MM to a deterministic and a Bayesian ODE system. The models
are calibrated to simulated time series data.
Results By means of the case study, we show that our methodology produces outcome
which is comparable to the “gold standard” of the Bayesian ODE system.
Conclusions In contrast to ODE systems in the literature, the dynamic MM includes
distributions on all model parameters at manageable computational effort (including cali-
bration). The run time of the Bayesian ODE system is 15 times longer.
1 Background
Vaccines, antibiotics and antivirals against infectious diseases offer health benefits to society [1,2]
and have been instrumental in the prevention and treatment of conditions previously causing
egregious burden to public health. Examples include the extremely low prevalence of syphillis,
the control of human immunodeficiency virus, the worldwide eradication of smallpox [3] and the
extremely low incidence of tetanus, diphteria and congenital rubella syndrome in the Western
world [4]. However, despite being frequently successful from a clinical point of view, vaccination
programmes and antiretrovirals are often costly to apply. As a pre-requisite to their implemen-
tation, health interventions such as vaccines are thus increasingly subject to cost-effectiveness
analyses (CEAs) [5, 6].
The National Institute for Health and Care Excellence (NICE) is arguably the leading health
technology assessment agency in the world. In the UK, NICE is responsible for providing guid-
ance and advice on whether proposed interventions should be publicly funded. NICE has devel-
oped a set of criteria and guidelines that drive the analytic process of CEA [7]. Crucially, these
involve the explicit necessity of assessing the impact of parameter uncertainty on the decision
making outcome, a process typically known as Probabilistic Sensitivity Analysis (PSA) [6, 8, 9].
In the UK, the appraisal of vaccines falls under the remit of the Joint Committee for Vac-
cines and Immunisations, an independent expert advisory committee to the ministers and health
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departments. Since 2009, the Health Protection Regulation obliges the Secretary of State to
ensure that recommendations for national vaccination programmes are based on an assessment
demonstrating cost-effectiveness [10]. However, there are currently no vaccine-specific guidelines
for developing clinical or cost-effectiveness evidence.
One of the reasons for this circumstance is perhaps the intrinsic complexity of infectious dis-
ease modelling, which is typically performed through compartmental models. These are highly
complicated mathematical tools capable of simulating the natural history of disease infection and
progression. More specifically, in pathogens transmissible among humans, these models need to
account for population dynamics and herd immunity [11]. Herd immunity implies that due to
lower infection prevalence, the introduction of preventive and therapeutic measures such as vacci-
nation, quarantine, antivirals and antibiotics induces a reduced risk of pathogen exposure. Only
dynamic models are able to prevent incorrect predictions since they are suitable to incorporate
these effects [12–14].
Dynamic compartmental models are commonly fitted by solving systems of Ordinary Differ-
ential Equations (ODEs) in continuous time. While these deterministic models usually deal with
features such as herd immunity (and thus are considered the “industry standard” in infectious
disease modelling), they are characterised by a notable computational effort. One important
consequence is that, in most cases, epidemiological and economic modelling for infectious dis-
ease performed by means of ODEs is based on the inclusion of fixed, predefined values on the
model parameters. These fixed values are usually informed through a point estimate. The joint
uncertainty in the parameters is then not considered; these models result in outcome (e.g. on the
number of people in the states) which does not include distributions.
Therefore, PSA on the model outcome can only be conducted in retrospect and not in a
straightforward way. An additional step using Latin Hypercube Sampling or Monte Carlo sam-
pling is necessary, as shown in [15–17] and [18–20], respectively. Alternative methods that may
prove computationally efficient when estimated through polynomial chaos expansions as shown
in [21,22] are provided by the Sobol and Fourier amplitude sensitivity test (FAST) indices. These
indices are based on ANOVA techniques and thus estimate the total contribution of each model
parameter or a combination of parameters to the variance of the model output [23,24]. However,
in contrast to a full PSA, uncertainty is not propagated through the whole model.
The computational feasibility of PSA in retrospect is limited in models which include a high
number of states and model parameters. In addition, in contrast to a Bayesian approach, pa-
rameter uncertainty is not propagated through the crucial model parts of pathogen transmission
and disease progression. The outcome based on fixed parameter values can differ considerably
from the PSA outcome, and the two are in most cases not reported in enough detail to identify
possible inconsistencies (with the exception of [19]). The results presented commonly focus on
uncertainty in the health economic rather than the prevalence outcome of the models, and PSA
results on infection prevalence including the corresponding confidence intervals are often not
given [18, 20, 25]. This approach is highly questionable, especially with respect to consistency
with validation targets. To ensure that the model outcome on the number of people in the states
and infection prevalence is realistic, calibration to high quality data based on large sample size
is necessary. This is often not conducted [25], or only conducted on the outcome based on fixed
parameter values [18]; the PSA outcome on prevalence is usually not evaluated with respect to
fitting high quality data [19,20,26].
The more complex an ODE system especially with respect to state space and number of
model parameters, the larger the effort on implementation and computation, especially if each
model parameter is assigned a suitable distribution. This might be one of the reasons why the
International Society for Pharmacoeconomics and Outcomes Research guideline for best mod-
elling practice in infectious disease suggests that PSA is not a fundamental component of health
economic assessment [12]. This recommendation is given in contrast with NICE and virtually
any other disease area. As a consequence, most economic models for vaccines only consider
2
deterministic sensitivity analysis, which is based on selecting a grid of “plausible” values for a
subset of model parameters in order to assess the robustness of the decision-making process. This
approach is however not recommended in general, as it fails to account for potential correlation
among the parameters [6, 9, 27].
In contrast to ODE-based models, systems of equations can also be defined in discrete-time,
which are termed difference equation models [28]. An alternative compartmental specification is
given by Markov models (MMs). MMs are used to model progression over time across a finite
set of states. Since MMs are described by a stochastic process, these are classified as stochastic
models. This is in contrast to ODE systems and difference equation models, which belong to the
class of deterministic models. In a deterministic model, the same set of parameter values and
initial conditions always results in the same output. In contrast, a stochastic model produces
different output each time the model is run, accounting for randomness. Apart from the model
class, difference equation models and discrete-time MMs are mathematically comparable.
Although MMs can also be computationally intensive, it is generally feasible to implement
even complex models in a Bayesian framework or to use re-sampling methods such as the boot-
strap to characterise the uncertainty in the model parameters. Perhaps for this reason, MMs
are a very popular tool in health economic evaluation. Nevertheless, a major limitation in
infectious disease modelling is that they are intrinsically static, i.e. they do not account for
population dynamics [29].
We introduce in this paper an extension to standard MMs, which we term “dynamic Bayesian
MM” to indicate that we consider a stochastic model and use a Bayesian framework to estimate
its underlying parameters. We directly include the force of infection of the pathogen, which
automatically accounts for time-dependent changes in prevalence and thus the effects of herd im-
munity, into the state allocation algorithm of a MM. In other words, the movement of susceptibles
to the state of infection is directly represented by the dynamic force of infection. A direct inclu-
sion of the force of infection into the state allocation algorithm of a difference equation model [30],
a MM [31, 32] or its direct consideration in a model based on a stochastic process [33–35] was
presented previously by several authors. However, the authors who present stochastic models
do not conduct a health economic evaluation. In the health economics literature, to the best of
our knowledge, no approach of a dynamic MM including a high number of states and suitable
probability distributions on all model parameters is presented.
Our dynamic Bayesian MM combines six advantages in comparison to the few dynamic MMs
presented in the literature. Firstly, in contrast to our contribution, the compartmental models in
the literature are only suitable to include a low number of states due to computational limitations
and the majority consist of no more than four states (apart from [30]). Our methodology is
especially suitable to incorporate an extensive number of states as described elsewhere [36] for
the application to human papillomavirus (HPV) modelling. In our model on HPV, 36 states
in females and 22 states in males are included to account for all known HPV-induced diseases
apart from recurrent respiratory papillomatosis. In addition, statisticians or health economic
modellers can implement our approach directly in the commonly used software R linking to JAGS
or WinBUGS; the corresponding run-time is considerably fast, and therefore, it is not necessary
to use a compiled language such as C which is usually not widely used in this field. The four
remaining advantages are given through the Bayesian framework, which i) is highly flexible
with its probabilistic nature since it considers multiple sources of prior information in terms of
evidence synthesis [37], ii) enables propagation of parameter uncertainty through the infection
transmission, progression and economic evaluation process, iii) ensures that calibration targets
are met through a constant updating process of the outcome on the numbers of people in the
states directly in the state allocation algorithm, using available time series data, and iv) simplifies
the process of PSA, an essential part of CEAs, avoiding the necessity of applying additional
sampling techniques such as Monte Carlo or Latin Hypercube Sampling once the model output
is available.
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The paper is structured as follows: Firstly, we describe compartmental models in widespread
use for CEAs on interventions against infectious diseases. Secondly, we introduce our contribution
of the dynamic Bayesian MM. Thirdly, we compare the performance of an ODE system including
fixed values on the model parameters and an ODE system in a Bayesian framework to our
methodology, using a case study of a chronic sexually transmitted infection. To contrast the
three methodologies in practice, we compare the natural history of disease following calibration,
and conduct CEAs including PSA, comparing a screening strategy to a hypothetical vaccine.
Finally, we discuss advantages and disadvantages of ODE-based methodology in comparison to
the dynamic Bayesian MM.
2 Methods
Compartmental models consist of a set S of mutually exclusive and exhaustive states describing
disease infection and progression. We indicate the elements of S as s = 1, . . . , S. Members of a
“virtual” population move across the states over a pre-specified time horizon.
Figure 1 shows an example of a compartmental model incorporating the natural disease
history of a chronic sexually transmitted infection (STI) with S = 5 states which is deemed
similar to HIV [38]. The assumptions encoded by this structure are that the whole population
initially is in the state Susceptible (indexed by s = 1), from which a proportion can move to
the state Infected (s = 2). Following this, people move to an Asymptomatic state (s = 3). A
progression to the state Morbid (s = 4) induces the development of disease symptoms. The state
Dead (s = 5) can be reached from any state; people die due to any cause or as a consequence of
being in the state Morbid. Compared to the average population, the latter have a higher risk of
death. A transition from one state to another is defined according to transition parameters [39].
They are indicated as φr,s, where r, s ∈ S represent the original and target state, respectively.
People proliferate at a rate χ, resulting in a replenishment of the pool of susceptibles at risk of
contracting the infection.
1. Susceptible 2. Infected 3.Asymptomatic 4.Morbid
5.Dead
φ1,2 φ2,3 φ3,4
φ
1,5
φ
2
,5 φ 3
,5 φ4,5
χ
Figure 1: Model structure of a hypothetical chronic sexually transmitted infection. The arrows
represent the possible transitions. These are governed by the parameters φr,s with indices r, s ∈ S
representing origin and target states, respectively. The replenishment of the pool of susceptibles
by newborns proceeds at a rate χ.
Compartmental models may differ in two characteristics. The first is the specification of
time. The most realistic option is to allow transitions among the states at any point in time
t > 0; this is a so-called “continuous-time approach”. Alternatively, it is possible to assume that
transitions occur in discrete time where only one transition is possible within a pre-defined time
interval It = [t, t+ κ), where κ determines the corresponding interval width, commonly referred
to as cycle. Depending on the medical context, κ can be specified in terms of daily, weekly,
monthly or yearly cycles. The second difference concerns the way in which population dynamics
are considered: models including a force of infection which accounts for changes in prevalence
are referred to as dynamic, while those that include a fixed force of infection and thus ignore the
effects of herd immunity are termed static.
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In addition, different approaches to model parameter specification exist, which may have
major impact on the outcome of health economic evaluations. Depending on the methodology
used, the induced computational effort might not allow the inclusion of probability distributions
on all model parameters. In that case, the model parameters are fixed values. Commonly, these
are estimated through a relevant summary, e.g. mean, median or mode, obtained from available
data. The point estimate is then used as a plug-in for the corresponding parameter. In contrast,
if whole distributions of values are assigned, parameter uncertainty is propagated through the
infection progression. While frequentist versions of this strategy exist (e.g. based on bootstrap),
this type of modelling is most naturally handled within a Bayesian paradigm.
2.1 Ordinary Differential Equation models
ODE systems model the rate of change in the number of people within a given state in continuous
time; thus, the corresponding parameters are transition rates and we denote them as ρr,s(t), with
r, s ∈ S representing again the origin and target states, respectively. In principle, transition rates
can depend on t, but do not necessarily have to. The number of people transitioning in each
state at t is multiplied by the corresponding transition rates to obtain the inflow and outflow
to and from a state. The difference between the number of people entering and leaving a state
corresponds to the derivative of the number of those in the respective state.
Back to our example, we define the vector n(t) = (n1(t), . . . , nS(t))′, where ns(t) is the
number of people in state s at time t. The corresponding ODE system is given by the set of
equations
dn1(t)
dt
= χ[n1(t) + n2(t) + n3(t) + n4(t)]− ρ1,2(t)n1(t)− ρ1,5n1(t)
dn2(t)
dt
= ρ1,2(t)n1(t)− ρ2,3n2(t)− ρ2,5n2(t)
dn3(t)
dt
= ρ2,3n2(t)− ρ3,4n3(t)− ρ3,5n3(t)
dn4(t)
dt
= ρ3,4n3(t)− ρ4,5n4(t)
dn5(t)
dt
= ρ1,5n1(t) + ρ2,5n2(t) + ρ3,5n3(t) + ρ4,5n4(t).
(1)
The rate of change in the number of people in each state at each point in time t is subject
to population dynamics and exposure to sources of infection. The transition to the state of
infection is determined by the dynamic force of infection of the pathogen, indicated by ρ1,2(t)
in (1). This is a function of the probability of pathogen transmission, partner acquisition rates
and prevalence.
If each model parameter is assigned a fixed value, parameter uncertainty is not accounted
for. Scenario analyses are often performed, for example by estimating the parameters through
summary statistics at the extremes of the corresponding parameter distribution (e.g. lower
or upper quantiles, minima or maxima). As mentioned earlier, this is not equivalent to the
application of a full PSA.
Theoretically, it is possible to incorporate a probability distribution for each parameter of
an ODE-based model, for example in a Bayesian context. The uncertainty is then propagated
through the estimation procedure, which again generates a full distribution of outcomes. This
type of model can be analysed using for instance software based on Markov Chain Monte Carlo
(MCMC) algorithms such as WinBUGS [40] or Stan [41], a very promising tool, which in general
performs extremely well with relatively complex systems. Both include ODE solvers and can be
linked to the statistical programming language R.
In realistic problems including a large number of states and complex structures, assigning
a suitable distribution to all model parameters in ODE systems may be impractical since the
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model needs to be run for a large number of simulations to ensure convergence of each parameter
and thus the ODEs have to be solved repeatedly for each parameter combination. The increase
in the computational time is induced by the length of the observation time horizon, the amount
of parameters, the complexity of contacts, and most importantly by the number of states which
increases the number of differential equations. Consequently, complex ODE-based models which
incorporate distributions on all parameters are rare exceptions in the literature on infectious
disease transmission modelling [42].
2.2 Discrete-time Markov models
The main characteristic of MMs is the Markov assumption which implies that the transition to a
future state is exclusively conditional on the current state or on a limited set of previous states,
but not on the full trajectory. However, the Markov assumption can be relaxed by accounting
for covariates (e.g. age and sex) or for time-specific prevalence and population dynamics in the
transition parameters.
ODE systems and MMs differ in the way they describe the process of transitions. As suggested
earlier, in the former, the rates of change are calculated dynamically through differentiation, while
in the latter, the transitions are described by a static Markov process (a category of a stochastic
process). As for ODE-based models, MMs can be implemented for continuous time.
However, the vast majority of MMs in the health economic literature is based on a discrete-
time approach [43]. In this case, members of the population move across the states according
to a set of transition probabilities only once per time interval (termed “Markov cycle”). These
probabilities can be arranged in a matrix Π = (pir,s), whose elements represent the transition
probabilities for movements from an original state r to a target state s.
For the model structure of Figure 1, the transition probability matrix is defined as
Π =

pi1,1 pi1,2 0 0 pi1,5
0 pi2,2 pi2,3 0 pi2,5
0 0 pi3,3 pi3,4 pi3,5
0 0 0 pi4,4 pi4,5
0 0 0 0 1
 ,
implying that, for example, a susceptible either acquires the infection (with probability pi1,2), dies
(with probability pi1,5), or remains susceptible, which occurs with probability pi1,1 = 1−pi1,2−pi1,5.
If we define the vector nt = (n1t, . . . , nSt)′, where nst is the number of people in state s and
at each time interval It, then transitions across the states from one time interval to the next are
calculated as
nt+1 = Πnt. (2)
MMs are relatively straightforward to implement and are commonly used to model the pro-
gression of non-communicable conditions such as cardiovascular disease and cancer. Therefore,
they are established in the health economic literature and well-known to clinicians and decision
makers. However, the process of pathogen transmission is not estimated correctly using standard
MMs. A transition of susceptibles to the state of infection is commonly represented by a static
transition parameter which does not consider changes in the population prevalence over time.
These especially occur after the introduction of a preventive intervention such as vaccination into
a fully susceptible population.
The predictions of static MMs on population prevalence are commonly incorrect (although
notable exceptions include scenarios with very low vaccine coverage or pathogens that cannot
be transmitted between humans, e.g. tetanus). In the worst case, the whole model outcome
on infection prevalence and the related CEA can be incorrect, e.g. because of the impact of
an unrecognised shift in the age of infection of childhood diseases. Some childhood diseases are
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relatively harmless in young children but prone to lead to serious health issues in adults. Incorrect
predictions of static MMs on population health and induced costs, e.g. through hospitalisation
and treatment, can have dire consequences [29].
As for ODE-based models, a dynamic force of infection could be incorporated into the tran-
sition probabilities to account for the effects of herd immunity. However, to the best of our
knowledge, dynamic Markov models are not commonly used in the health economics literature.
2.3 Dynamic Bayesian Markov models
To overcome the limitations discussed above and with a view to extending the modelling frame-
work for health economic evaluation of interventions in infectious disease, our main idea is to add
a force of infection which depends on population dynamics and prevalence into a MM setting.
As a consequence, the transition probabilities from the state Susceptible to the state Infected
are directly defined by the dynamic force of infection. Specifically, we set up our model so that
the force of infection is calculated separately within each cycle of the state allocation algorithm
corresponding to (2) as a function of
• the probability of pathogen transmission per contact, which we indicate as β;
• the rate of contacts between susceptible and infectious members of the population ω; and
• the time-dependent pathogen prevalence
ψt =
It
Nt
,
where It represents the number of people in the state of infection and, assuming that state
S indicates death,
Nt =
S−1∑
s=1
nst
is the number of those alive at time interval It.
The force of infection is recalculated at each Markov cycle as
λt = βωψt. (3)
Since ω is a rate, (3) also results in a transition rate. Assuming that λt remains constant within
each time interval, the corresponding time-dependent transition probability for the discrete-time
MM is estimated as
pi1,2,t = 1− exp−λt . (4)
We acknowledge that the estimation of the force of infection may be only approximate, due
to the competing risk of death and the assumption of uniformity within the intervals It. This
assumption is not likely to hold if the disease is characterised by very fast transmission, or when
events associated with the infection are likely to occur in short periods of time. In these cases,
it is perhaps advisable to reduce the length κ of the cycles and the duration of the follow-up,
to avoid unrealistic estimates for the number of subjects in the states per cycle. For example,
for yearly cycle length, immediate death following infection would be delayed by up to one year.
These delays would then accumulate through the whole model and introduce a more substantial
bias at later follow-up.
However, a likelihood function for interval censored data could be estimated to account for
competing risks as shown in [44, 45] for an independent inspection process (IPP) model; this
model allows for future movements to be conditional on the history of the data. In Lemma 1,
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Hudgens et al. [44] present this likelihood under the assumption that only one event can occur per
cycle. As an alternative to (4), this likelihood could be derived for the cumulative distribution
function of an exponential model.
Moreover, competing risks could be considered through the Kolmogorov forward equations.
This alternative approach would allow for the possibility that more than one event could occur
per cycle; for instance, one could acquire the infection followed by death within the same cycle.
In order to move from the state Susceptible to Infected, one would have to take into account
that the infection was acquired and death did not occur within the remainder of that cycle. For
the exponential distribution, the corresponding Kolmogorov forward equation to estimate the
transition probability of moving between the two states was derived as
pi1,2,t = exp
−ρ1,5(t)
(
1− exp−λt
)
, (5)
accounting for ρ1,5(t), the transition rate of moving from the state Susceptible to Death. Replacing
(4) by (5), the accuracy of the approximation of pi1,2,t could improve. Notice, however, that in
the case study presented in Section 2.4, the probability of death is very low in susceptibles (who
are by definition in good health and of young age) and therefore this additional complication in
the estimation of the transition probability is not necessary. The results of the corresponding
discrete- and continuous-time models are comparable; the approximation in (4) is therefore
deemed sufficient.
The transition probability pi1,2,t approximated by (4) is multiplied by the proportion of the
population in the state Susceptible to provide an estimation of the contingent of movements to
the state Infected, effectively including dynamic, time-dependent changes in prevalence in the
corresponding transitions.
The computational effort is reduced by fitting models that do not involve complex ODEs,
while still allowing for mixing patterns within the population. Another potential advantage
of the dynamic MM framework is that it is fairly simple to incorporate suitable probability
distributions on all model parameters, even if the model is complex with an extremely large
number of parameters and states. In contrast, the related computational effort in a comparable
ODE-based model would be extremely high due to i) numerical integration, e.g. through the
Runge-Kutta solver [46]; ii) considerably smaller step sizes of ODE solvers when compared to the
cycle length of discrete-time models; and iii) accounting for competing risks in the transition rates
as elaborated above. The model can be easily extended to include a high number of age cohorts
for infectious diseases with age-specific prevalence such as HPV; we present this application
including 24 age cohorts at manageable computational effort elsewhere [36].
Accounting for parameter uncertainty is particularly relevant because, for obvious ethical
and practical reasons, it is invariably difficult (if possible at all) to obtain and use experimental
evidence to inform the pathogen transmission probability β and the active contact rate ω —
arguably the crucial parameters. Often observational studies or expert opinions are the only
available information with the consequence that large uncertainty remains over the most likely
range, let alone the “true” value of the parameters. A Bayesian approach may provide great
benefit in allowing this uncertainty to be fully propagated and perhaps in integrating different
sources of evidence (e.g. using evidence synthesis [39]); this indeed has been advocated for MMs
in the health economics literature [9, 39, 47]. In [48], β is assigned a Uniform distribution in
the interval [0;1], which essentially amounts to allowing any value (between 0 and 100%) as
equally possible. We have performed extensive sensitivity analysis to this parameter in the HPV
model and found that the prevalence outcome was highly sensitive to this parameter (results
not published).
In a Bayesian dynamic MM setting, it is possible to assign prior distributions to the pa-
rameters (β, ω) to represent the state of science — if data are available, these are updated into
posterior distributions although it is possible to still propagate uncertainty in the priors even
when no data on pathogen transmission or active contacts are observed. In addition, the quan-
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tity ψt is estimated for each cycle as a function of transition probabilities, which can also be
modelled using suitable distributions. This modelling process induces a probability distribution
on ψt and a fortiori also on λt, which is defined as a function of the three random parameters
(β, ω, ψt). Thus, the corresponding transition probabilities pi1,2,t are modelled probabilistically,
meaning that uncertainty in the population dynamics is propagated through the economic model.
If β and ω are varied simultaneously and difficult to inform directly using empirical evidence,
the force of infection may be subject to issues of non-identifiability, i.e. it is possible that it
cannot be distinguished to what extend differences in the corresponding outcome on the number
of subjects in the state Infected are induced by which parameter. Individuals become infected as
a consequence of meeting an infected subject (determined by β) once or several times (determined
by ω). However, we note here that we are mainly interested in the overall number of subjects
in the state Infected, irrespective of the number of contacts that are necessary to result in
an infection. Therefore, in the economy of our modelling framework, it is less important if
changes in the number of subjects in the state Infected are induced by β or ω. Nevertheless,
we do acknowledge this issue and suggest careful consideration of the prior assumptions when
investigating sensitivity of the results.
Another crucial aspect in infectious disease modelling (and more generally in statistical anal-
ysis) is that of calibration of the model output [49, 50]. The Bayesian framework enables the
calibration of the numbers of people in the states directly in the state allocation algorithm, using
available time series data for a specific time frame of follow-up. The corresponding details are
explained in Section 2.4.1 and Appendix B.
The BMM is generalizeable to any infectious disease which is transmitted between humans
and where interventions (e.g. quarantine, vaccination, antibiotic or antiviral treatment) are avail-
able to reduce infection prevalence. It is especially suitable to include an extremely high number
of states, model parameters with suitable distributions, and age cohorts as shown in [36].
To estimate the efficacy and cost-effectiveness of an intervention, only dynamic models pre-
dict realistic outcome and account for herd immunity in case of vaccination. Yet, any kind of
intervention which reduces prevalence has a protective impact on susceptibles who do not directly
receive it; this can be considered in the BMM.
Finally and specifically for the purpose of economic evaluation, the dynamic BMM has the
advantage that PSA can be performed “for free”, once the model output is produced. In a
Bayesian framework, the MCMC simulations for all the model parameters can be combined to
obtain a full characterisation of the uncertainty in the decision-making process. This can be
post-processed (e.g. using the R package BCEA [51]) to produce relevant summaries such as the
cost-effectiveness plane, the cost-effectiveness acceptability curve and the analysis of the value
of information (see Section 3.2).
Our approach to a dynamic BMM provides PSA samples directly as part of the probabilistic
model output. Therefore, in addition to simpler probabilistic sensitivity analysis (e.g. based on
CEACs), the BMM enables the conduct of extensive Value of Information (VoI) analysis, which
can be used to prioritise further research on key model inputs, currently driving uncertainty in the
decision making process. For example, recent methods have been developed for fast computation
of both the Expected Value of Partial Perfect Information (EVPPI) and the Expected Value of
Sample Information (EVSI) [52–54] that use simulations from the model parameters obtained
directly during the process of PSA. The BMM conforms with this structure and would thus be
suitable for VoI analysis based on these methods, without the need to divorce the transmission
model from the economic evaluation, as often happens in current practice.
2.4 Case study
We consider again the fictional chronic STI described above and compare the dynamic Bayesian
MM to both a deterministic and a Bayesian ODE system. We denote the three models as BMM,
dODE and BODE, respectively. We evaluate whether our BMM produces results that are in
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line with the “gold standard” of the BODE. In the three models, we distinguish between sexes
as well as high- and low-risk sexual behaviour. The duration of the follow-up is set at 100 years,
with a yearly Markov cycle length. We consider a population size of 1,000,000 and initially
assume that 600 people are infected, whereas the remainder are susceptible. Males amount to
50% and the high-risk group to 20% of the population; the sex ratio in the two risk groups
is constant. The proportion of infected people in both sexes and risk groups is identical. We
account for sex-specific differences in sexual behaviour, assuming higher partner acquisition rates
in males. The population size changes due to births and deaths. We conduct our analysis for
two competing health-care interventions. We assume that in the status-quo, screening takes
place at intervals of five years at a pre-defined rate to enable an early detection of the STI. For
simplicity, we assume that under the vaccination scenario no screening takes place. We assume
that the vaccine is only effective before initial STI infection; thus, susceptibles are vaccinated at
a specified vaccine uptake rate at intervals of five years. Following STI diagnosis, treatment is
provided in both interventions.
In the dODE and BODE, the force of infection (transition rate from the state Susceptible
to the state Infected) shown in (3) has to be adjusted to account for the covariates sex and
behaviour with respect to infection prevalence. In the BMM, the sex- and behavioural-specific
transition probability is estimated by transforming this adjusted transition rate according to
(4). For simplicity, we exclusively account for random mixing. Further details are given in
Appendix A.
2.4.1 Model parameters and related distributions
In addition to the probability of STI transmission β and the partner acquisition rates ωvb, the
model contains a variety of parameters such as those determining the screening and vaccine
coverage, the unit costs of STI diagnostics and treatment and the health utilities, which are
relevant in context of the cost-effectiveness analysis. We assign informative priors to transition
parameters and costs (defined in monetary units of £) and utilities. We specify the distributional
assumptions so that the outputs of the health economic evaluation are within reasonable ranges.
We assign informative or minimally-informative priors to the remaining parameters and update
these through simulated individual-level and aggregate data into the corresponding posteriors.
Using simulated data is reasonable since the case study is fictional. For example, we pretend
that data on partner acquisition rates ωvb are available from a large data registry. To infer
ωvb, we update informative Gamma priors into the corresponding posteriors through Poisson-
Gamma models. Beta-Binomial models are used to infer probabilities (e.g. the vaccine coverage
α and efficacy γ, which are informed by data). We assume to have access to vaccination data
of 500 individuals of whom 450 have received the vaccine. In addition, we assume to have the
information that in 450 out of 500 people who received the vaccine, it was effective.
Table 1 shows an overview of the model parameters θ = {ωvb, χ, β, pir,s, τ, ξ, γ, σ, c, us}. The
means and 95% credible intervals are displayed for the BMM (the values in the BODE are
comparable) and rounded to two decimal places. However, the 95% CI of the parameter χ is in
fact defined as [0.009420;0.010596]. Since the BMM is based on a discrete-time approach, the
corresponding transition probabilities are modelled using Beta distributions. In contrast, the
transition rates of the continuous-time BODE are modelled using Gamma distributions. The
transition probabilities for movements from the states Susceptible, Infected and Asymptomatic
to Dead are assumed as identical; thus, only pi1,5 is shown.
Depending on the medical context, correlations between posterior distributions are possible
and informative priors can result in quite different posterior distributions, if they are influenced by
the updating process of other priors. This might occur in parameters which are not independent,
for example transition parameters to certain states calculated by means of hierarchical models.
In this respect, the transition probability to the state Dead might be dependent on one to a less
severe state such as Morbid. Potential correlation is automatically accounted for in the PSA.
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Table 1: Overview of the informative priors and the models used for updating informative and
minimally-informative priors. The values are fictional and were chosen so as to produce most
realistic prevalence outcome and cost-effectiveness results.
Parameter Description Distribution/model BMM Distribution/model BODE Mean 2.5/97.5% percentiles
ωMH Partner acquisition rate
(high-risk males)
Poisson-Gamma model equivalent to BMM 9.10 [8.77;9.29]
ωML Partner acquisition rate
(low-risk males)
Poisson-Gamma model equivalent to BMM 2.98 [2.82;3.12]
ωFH Partner acquisition rate
(high-risk females)
Poisson-Gamma model equivalent to BMM 9.00 [8.71;9.26]
ωFL Partner acquisition rate
(low-risk females)
Poisson-Gamma model equivalent to BMM 1.96 [1.86;2.09]
χ Proliferation parameter Gamma(1111.1,111111.1) Gamma(1111.1,111111.1) 0.01 [0.01;0.01]
β STI transmission probabil-
ity per partnership
Beta-Binomial model equivalent to BMM 0.16 [0.15;0.16]
pi2,3 Transition parameter from
state 2 to state 3
Beta(5119.2, 1279.8) Gamma(25600,32000) 0.80 [0.79;0.81]
pi3,4 Transition parameter from
state 3 to state 4
Beta(1842.66, 18631.34) Gamma(2025,22500) 0.09 [0.09;0.09]
pi4,5 Transition parameter from
state 4 to state 5
Beta(1535.96, 36863.04) Gamma(1600,40000) 0.04 [0.04;0.04]
pi1,5 Transition parameter from
state 1 to state 5
Beta(156.171, 312186.6) Gamma(156.25,312500) <0.01 [<0.01;<0.01]
η Probability of STI diagno-
sis
Beta-Binomial model equivalent to BMM 0.90 [0.88;0.92]
σ Screening probability Beta-Binomial model equivalent to BMM 0.90 [0.87;0.92]
α Vaccine coverage parame-
ter
Beta-Binomial model equivalent to BMM 0.90 [0.87;0.92]
γ Vaccine efficacy parameter Beta-Binomial model equivalent to BMM 0.90 [0.87;0.92]
cscreen Unit cost of screening in £ Lognormal(2.996, 0.693) equivalent to BMM 25.39 [5.19;77.53]
cvac Unit cost of vaccination
in £
Lognormal(5.011, 0.01) equivalent to BMM 150.02 [147.14;152.98]
ctest Unit cost of STI test in £ Lognormal(2.996, 0.03) equivalent to BMM 20.01 [18.83;21.19]
cblood Unit cost of blood test in
£
Lognormal(3.401, 0.03) equivalent to BMM 30 [28.26;31.79]
ctreat Unit cost of treatment in £ Lognormal(8.517, 0.015) equivalent to BMM 4999.78 [4853.56;5149.24]
cdis Unit cost of disease treat-
ment in £
Lognormal(9.210, 0.01) equivalent to BMM 9999.95 [9802.97;10198.10]
cgp Unit cost of visit to general
practitioner in £
Lognormal(3.912, 0.02) equivalent to BMM 50.01 [48.08;52.01]
u2 Health utility of infected
(min=0, max=1)
Beta(1469.3, 629.7) equivalent to BMM 0.70 [0.68;0.72]
u3 Health utility of asymp-
tomatic (min=0, max=1)
Beta(1439.4, 959.6) equivalent to BMM 0.60 [0.58;0.62]
u4 Health utility of morbid
(min=0, max=1)
Beta(629.7, 1469.3) equivalent to BMM 0.30 [0.28;0.32]
The dODE is calibrated through a frequentist probabilistic calibration approach [50, 55],
whereas the BODE and BMM are calibrated through Bayesian calibration approaches [56, 57].
The first involves the calculation of goodness-of-fit statistics. The advantage of the latter is
that the model parameters can be inferred by fitting the models to data directly (in one step).
Simulated time series data on the number of high-risk people in the states Susceptible, Infected,
Asymptomatic and Morbid in the first five years of follow-up are used for calibration. A short
observation time horizon of only a couple of years (five years in this case) is common in available
time series data. These data are simulated by running the dODE under the status quo for a
follow-up period of five years; the input parameter values are informed through the means of
the parameters of the BODE. In many infectious diseases, only data on the number of infected
individuals are available. The model code can easily be adapted to only calibrate the outcome
on one of the states since every state is calibrated separately. Further details are given in
Appendix B.
The dODE is estimated using a combination of the R packages EpiModel [58] and deSolve [59].
As for the BMM and BODE, we estimate the model parameters using a MCMC procedure; we
run two chains with a total of 1,000 simulations after convergence. In this setting, convergence
is sufficiently achieved with a Potential Scale Reduction Rˆ < 1.1 in all model parameters [49],
and there are no issues with autocorrelation. We fit the BODE in WinBUGS through the ODE
solver interface WBDiff [60]. The BMM is estimated using WinBUGS and JAGS [61], an alternative,
established software to perform Gibbs sampling, in order to compare computational efficiency.
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The models are run on a Dell Latitude E6320 (Intel Core i5-2520M, 2x4GB DDR3 RAM,
500GB SATA HDD (2.5", 7200rpm)). The computation times are 4,480.19 seconds (around 1
hour 15 minutes) and 6,587.67 seconds (around 1 hour 50 minutes) for the dODE and BODE,
respectively. Interestingly, the BMM runs much faster in JAGS (149.81 seconds) than in WinBUGS
(449.42 seconds). This difference is perhaps due to the way in which the two programmes handle
logical nodes, which are instrumental to defining the state allocation algorithm (see (2)). All
run times include model calibration which considerably increases the computational effort in the
ODE systems, but not for the BMM. The relevant model codes are presented in Appendix C.
As discussed in Section 2.3, identifiability could also become an issue when the posteriors
of β and ω are multimodal, which may happen if certain parameter combinations are more
likely to favour the data on partner acquisition rates and STI transmission probabilities. As a
consequence, the sampling algorithm could get stuck in one of the local modes, resulting in biased
summary statistics. We generate different initial values for each Markov chain to reduce the risk
that parts of the posterior distribution are not visited when producing the relevant samples. In
addition, we evaluate whether the two chains show proper mixing through trace plots.
3 Results
3.1 Natural history of disease
Figure 2 shows the outcome on the natural history of the fictional chronic STI following calibra-
tion. Only the results on high-risk females are displayed; those on high-risk males are compa-
rable. The BMM produces results which are comparable to the “gold standard” of the BODE.
The model outcome on the states Susceptible and Morbid of the BMM and BODE is basically
identical, whereas the outcome of the BODE shows slightly higher estimates on the number of
infected and asymptomatic high-risk females. The outcome on the number of susceptible and
morbid high-risk females is higher in the dODE; in contrast, the outcome on those in the states
Infected and Asymptomatic is lower when compared to the two Bayesian models. The ranges of
the 95% credible intervals of the BODE and BMM are similar, showing wider ranges in the BMM.
The 97.5% quantiles of the scenario analysis of the dODE are lower than the upper bounds of
the 95% CIs in the states Infected and Asymptomatic and higher in the states Susceptible and
Morbid, whereas the 2.5% quantiles are considerably lower than the lower bounds of the CIs
(apart from the state Susceptible).
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Figure 2: Calibration results on the number of high-risk females in the states following a sys-
tematic probabilistic calibration approach. The results of the Bayesian models are similar, with
a slightly higher number of high-risk females in the states Infected and Asymptomatic estimated
by the Bayesian ODE-based model. In contrast, the deterministic ODE-based model results in
a lower estimate on the number of high-risk females in the states Infected and Asymptomatic;
however, the outcome on the state Morbid is reversed.
3.2 Cost-effectiveness analysis
We denote the unit costs and utilities as csti and us, with indices s, t and i representing states
s ∈ {1, ..., S}, observation time points t and interventions i = 1 (status quo) and i = 2 (vac-
cination). We assume decreasing utility values for more severe states. Costs are induced by
screening, vaccination, a visit at the general practitioner and diagnostic tests. Following a posi-
tive STI diagnosis, further diagnostic tests and treatment are necessary. For all these quantities,
the distributional assumptions are presented in Table 1.
The overall costs per intervention are calculated as
Ci =
T∑
t=1
S∑
s=1
csinsti
(1 + δ)t−1
,
where nsti are the number of people in state s at time t when intervention i is applied and δ
is the yearly discount rate. In both the continuous- and discrete-time approaches, the model
13
output on the natural history of disease infection and progression is evaluated at pre-specified
time points t ∈ {1, ..., T}, where T represents the end of follow-up. We discount both costs and
benefits at a fixed yearly rate δ = 0.03, following ISPOR recommendations [62]. Similarly, the
overall utilities are computed as
Ui =
T∑
t=1
S∑
s=1
usnsti
(1 + δ)t−1
.
Overall costs and utilities define the monetary net benefit NBi(θ) = kUi−Ci. The economic
evaluation is performed by calculating suitable summaries such as the increment in mean cost
∆c = C2 − C1 and the increment in mean effectiveness ∆e = U2 − U1 between vaccination and
the status-quo, or the incremental cost-effectiveness ratio
ICER =
E[∆c]
E[∆e]
.
In the BMM and BODE, these quantities are estimated directly as function of the parameters,
while in the dODE, we conduct a scenario analysis including the 2.5% and 97.5% quantiles of
the ICER to evaluate the range of “plausible” results. A cut-off point of a willingness-to-pay k
of approximately £20,000 – £30,000 per QALY gained, adopted by NICE [63], is used as the
benchmark of value for money.
As for PSA, it is usually based on: (i) the analysis of the cost-effectiveness plane, depict-
ing the joint probability distribution of (∆e,∆c); (ii) the cost-effectiveness acceptability curve
CEAC = Pr(k∆e −∆c > 0), which shows the probability that the reference intervention is cost-
effective as a function of the willingness to pay k; and (iii) the expected value of “perfect”
information
EVPI = Eθ
[
max
i
NBi (θ)
]
−max
i
Eθ [NBi (θ)] ,
which quantifies the maximum amount of money that the decision-maker should be willing to
invest (e.g. in a new study) in order to resolve parameter uncertainty and thus make a “better”
decision. The Bayesian models can perform these analyses in a straightforward way, since these
quantities are all functions of the model parameters and thus a full posterior distribution can be
directly obtained.
The ICER of the dODE results in £ 7,203.416, ranging between £ 2,592.44 and £ 469,906 in the
scenario analysis at the 2.5% and 97.5% quantiles. The ICERs of the Bayesian models are compa-
rable to the dODE, resulting in £ 6,054.82 and £ 6,287.62 in the BODE and BMM, respectively.
Figure 3 displays the cost-effectiveness plane. Each point of the MCMC simulation lies within
the grey sustainability area, indicating that STI vaccination is cost-effective at a threshold of
£ 25,000 when compared to STI screening. STI vaccination is deemed to be both more expensive
and more effective than STI screening since all points are located in the upper right quadrant
of the graph. The corresponding ICERs of the BMM and BODE are displayed as red and blue
dots, respectively.
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Figure 3: Cost-effectiveness planes of the Bayesian ODE system and Bayesian Markov model.
The cost-effectiveness plane indicates that vaccination is both more expensive and more effective
than the status quo. All points lie within the sustainability area of cost-effectiveness. The ICERs
of £ 6,054.82 (blue dot, BODE) and £ 6,287.62 (red dot, BMM) indicate cost-effectiveness of STI
vaccination in comparison to STI screening at a threshold of £ 25,000.
Figure 4 shows the results of the CEACs and the population EVPIs of the two Bayesian
models. The amount of uncertainty in the BMM is slightly larger than in the BODE; however,
80% cost-effectiveness is clearly reached at the break-even points of the ICERs of both models.
The population EVPI of the BMM at around £ 500,000,000 is higher than in the BODE, where
it reaches a value of around £ 400,000,000. The higher EVPI value of the BMM is a consequence
of the slightly larger amount of uncertainty. Thus, the value of additional research is higher in
the BMM.
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Figure 4: Cost-effectiveness acceptability curves and expected value of information of the
Bayesian ODE system and Bayesian Markov model. The results of the BMM are displayed
in grey, whereas those of the BODE are shown in black. The amount of parameter uncertainty
is higher in the BMM. The CEACs in the left panel reach values of 80% at a willingness-to-pay
corresponding to the ICERs. The EVPIs for the whole population at around £ 500,000,000 and
£ 400,000,000 in the BMM and BODE, respectively, are shown in the right panel.
4 Discussion
In this paper we have presented a comparison of modelling methods for the economic evaluation
of interventions in infectious disease. We acknowledge that ODE-based models have several ad-
vantages and consider the Bayesian ODE structure as ideal to combine transmission modelling
with economic evaluation. However, including a large number of states and probability distri-
butions on a high number of model parameters induces computational issues, which effectively
acts as a barrier to the application of complex economic modelling in this area. This possibly
explains why the extensive application of PSA is limited in comparison to many other disease
areas, in health economics.
From the technical point of view, constructing a BMM is relatively simple and does not require
the use of specialised software — in fact our analysis has been performed using R and the Gibbs
sampler JAGS, which are often used by statisticians and health economic modellers and thus by
reviewers and advisers for health technology assessment agencies. This may again facilitate the
communication of complex modelling assumptions and thus the economic assessment of complex
interventions such as those based on vaccination programmes.
We of course acknowledge that the run time of the BODE could be reduced, for example
using optimised code implemented in C. This is also true of the BMM, which could be coded
using C directly. We note, however that a Bayesian implementation of an ODE system is more
computationally intensive than the corresponding deterministic version, due to the MCMC com-
ponent needed to obtain the estimate for the posterior distributions of the relevant parameters.
In addition, our proposal aims at giving a general framework: it is possible that in specific cases
modellers will be able to write highly optimised code that reduces the computational time. In
general terms, however, our experience suggests that many modellers working in health economic
evaluation would not be necessarily familiar with specialised code (e.g. C).
Moreover, it is important that the code used to provide the evaluation of the transmission
model is made available to reviewers (e.g. NICE appraisal committee), among whom a language
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such as WinBUGS is familiar, but other, more advanced programming languages are not. Finally,
the possibility of estimating the transmission model and embedding in the economic model has
the potential to improve the overall process (because the modellers developing the latter would
be equipped with the technical expertise to develop the former too).
In addition to language, a more crucial point with respect to computational efficacy is given
by the choice of the MCMC sampler. An alternative to a Gibbs sampler would for example
be Hamiltonian Monte Carlo (HMC), which is a more efficient algorithm. Random walks are
avoided using HMC since the gradient information is used. As a consequence, the algorithm is
able to sample more efficiently from regions of high probability [64].
5 Conclusion
Our proposal of a dynamic Bayesian Markov model can be seen as an effective compromise
between the ideal ODE-based models including suitable distributions on all model parameters
and simpler structures of MMs that fail to account for time-dependent changes in prevalence
and the effects of herd immunity. While providing a sparser temporal resolution in the way in
which transmission is modelled, our methodology has the advantage of accounting for param-
eter uncertainty. This in turn means that standard economic analysis, including PSA, can be
performed in a straightforward way. In addition, Markov models are a well established tool in
health economics, which may facilitate the translation of the modellers’ work to the regulators
and assessors.
In the fictional example presented in this paper, our BMM performs just as well as the BODE,
with seizable computational savings. Model predictions should always be calibrated, given time
series or prevalence data are available. Systematic calibration approaches usually induce a con-
siderably high computational effort. We could show that including a direct calibration approach
in the Bayesian models, the BMM runs 15 times faster than the BODE.
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Appendix
A Sex- and behaviour-specific force of infection
In the case study described in Section 2.4, the force of infection presented in (3) is adjusted to
additionally account for sex and behaviour. The indices v, v′ = (Male, F emale) indicate the
respective sex and its opposite. For example, a male is represented through the index M ; the
index of his female mixing partner is F . The sexual behaviour group is represented through
the index b = (Low, High). In the ODE models, the transition rate ρv,b,1,2(t) from the state
Susceptible to the state Infected depends on the covariates sex and behaviour. In the BMM,
the sex- and behavioural specific transition probability piv,b,1,2,t is estimated by transforming
ρv,b,1,2(t) according to (4).
For simplicity, we exclusively account for random mixing; members of the population of sex
v randomly select sexual partners of the opposite sex v′. Because of the impact of the covariates,
the estimation of the overall prevalence in the sexual partners of sex v′ is a weighted average of
the prevalence in both behaviour groups of sex v′. We show the corresponding equations for the
continuous-time approach as functions of t; for a discrete-time approach, these are similar.
The time-specific probability of selecting a partner from the high-risk group, which we indicate
as gv′H(t), depends on the partner acquisition rates ωv′H and ωv′L as well as on the population
sizes Nv′H(t) and Nv′L(t). The probability of selecting a partner from the low-risk group is
represented by gv′L(t). The corresponding equations adapted from [28] only account for two
sexual behaviour groups and are thus extended for sex, to give
gv′H(t) =
ωv′HNv′H(t)
ωv′HNv′H(t) + ωv′LNv′L(t)
gv′L(t) = 1− gv′H(t).
We estimate the sex-, behavioural- and time-specific force of infection
ρv,b,1,2(t) = βωvbψv′(t),
where
ψv′(t) =
(
gv′H(t)
Iv′H(t)
Nv′H(t)
+ gv′L(t)
Iv′L(t)
Nv′L(t)
)
is the weighted average of the STI population prevalence, which is estimated as a function of
the probabilities gv′b(t) of selecting a partner of the opposite sex from one of the two sexual
behaviour groups and the time-, sex- and behavioural-specific population prevalence Iv′b(t)Nv′b(t) . The
number of infectious people Iv′b(t) is estimated as those in the state Infected of the respective
sex and behaviour group. In line with (3), the force of infection ρv,b,1,2(t) is a function of the STI
transmission probability per partnership β, the partner acquisition rates ωvb, and the population
prevalence ψv′(t).
B Model calibration
The dODE is calibrated through a frequentist probabilistic calibration approach [50, 55]. Suit-
able distributions are assigned to the model parameters which are relevant in terms of natural
history of disease. As a next step, sets of 50,000 parameter combinations are sampled from the
distributions through Monte Carlo sampling. We calculate the sum of squared errors between
the outputs of the model runs (for each parameter set combination) and simulated data for the
first five years of follow-up in four states as
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Q(θ) =
5∑
t=1
4∑
s=1
[ys(t)− fs (t | θ)]2 .
The dODE is based on a continuous-time approach; however, the corresponding output is
evaluated at yearly time intervals t ∈ {1, ..., 5}. The simulated data on the number of high-risk
people in state s at time t are indicated by ys(t), and fs(t | θ) is the model output on high-risk
people given the input parameter set θ. As a final step, the set θ corresponding to the output
which results in the least sum of squares is selected; it is displayed in Table 2.
Table 2: Point estimates of the parameters of the deterministic ODE-based model obtained
through a frequentist probabilistic calibration approach. The parameter set θ with the best fit
to simulated data minimises the sum of squared errors.
Parameter Description Point estimate
ωMH Partner acquisition rate (high-risk males) 8.3515
ωML Partner acquisition rate (low-risk males) 2.4526
ωFH Partner acquisition rate (high-risk females) 8.3836
ωFL Partner acquisition rate (low-risk females) 1.6085
χ Proliferation parameter 0.0100
β STI transmission probability per partnership 0.1639
pi2,3 Transition parameter from state 2 to state 3 0.7957
pi3,4 Transition parameter from state 3 to state 4 0.0891
pi4,5 Transition parameter from state 4 to state 5 0.0232
pi1,5 Transition parameter from state 1 to state 5 0.0005
In contrast to the dODE, the BMM and BODE are calibrated through a Bayesian calibration
approach [56,57]. As described in Section 2.4.1, the advantage is that model parameters can be
inferred by fitting the models to data directly (in one step).
In a Bayesian framework, data can be considered in several ways. We include simulated data
on a selection of parameters to update the priors into the corresponding posteriors. However,
this only ensures that the corresponding parameters are informed by available evidence. Despite
posterior sampling, it could still be possible that the predicted outcome implied by the Bayesian
models was not comparable to high-quality data obtained from large data registries. In the
BODE, the output on the number of people in the states over follow-up corresponds to the
solutions of the ODEs. In the BMM, the output corresponds to the solutions of the state
allocation algorithm, which is given by (2). In addition to posterior sampling, the outputs of
both models are constantly updated through the simulated time series data. In fact, this is an
additional process of Bayesian inference, updating the model outcome through additional data.
The updating takes place by assigning Poisson distributions to the data; the event rate λ is
then represented by the solutions of the ODEs and the state allocation algorithm, respectively.
The resulting model outcome is already calibrated, and no further steps such as the calculation
of goodness-of-fit statistics are necessary. The evaluation of the natural history of disease and
the cost-effectiveness analysis including PSA can be conducted straightforwardly.
C Code of the case study
C.1 The Bayesian ODE-based model
model{
#define ODEs in WBDiff syntax
solution [1:n.grid ,1:dim ,1:2]<-ode(init [1:dim ,1:2], grid [1:n.grid],D(y[1:dim ,1:2] ,t),origin ,tol)
#ODEs for interventions i=1 (screening only) and i=2 (vaccination)
for(i in 1:2){
#ODEs for low -risk females
#Susceptible
D(y[1,i],t) <-chi*nfemL[i]-lambdafemL[i]*y[1,i]-rhosd*y[1,i]
#Infected
D(y[2,i],t) <-lambdafemL[i]*y[1,i]-rhoia*y[2,i]-rhosd*y[2,i]
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#Asymptomatic
D(y[3,i],t) <-rhoia*y[2,i]-rhoam*y[3,i]-rhosd*y[3,i]
#Morbid
D(y[4,i],t) <-rhoam*y[3,i]-rhomd*y[4,i]-rhosd*y[4,i]
#Dead
D(y[5,i],t) <-rhosd*nfemL[i]+ rhomd*y[4,i]
#ODEs for high -risk females
#Susceptible
D(y[6,i],t) <-chi*nfemH[i]-lambdafemH[i]*y[6,i]-rhosd*y[6,i]
#Infected
D(y[7,i],t) <-lambdafemH[i]*y[6,i]-rhoia*y[7,i]-rhosd*y[7,i]
#Asymptomatic
D(y[8,i],t) <-rhoia*y[7,i]-rhoam*y[8,i]-rhosd*y[8,i]
#Morbid
D(y[9,i],t) <-rhoam*y[8,i]-rhomd*y[9,i]-rhosd*y[9,i]
#Dead
D(y[10,i],t) <-rhosd*nfemH[i]+rhomd*y[9,i]
#ODEs for low -risk males
#Susceptible
D(y[11,i],t) <-chi*nmalL[i]-lambdamalL[i]*y[11,i]-rhosd*y[11,i]
#Infected
D(y[12,i],t) <-lambdamalL[i]*y[11,i]-rhoia*y[12,i]-rhosd*y[12,i]
#Asymptomatic
D(y[13,i],t) <-rhoia*y[12,i]-rhoam*y[13,i]-rhosd*y[13,i]
#Morbid
D(y[14,i],t) <-rhoam*y[13,i]-rhomd*y[14,i]-rhosd*y[14,i]
#Dead
D(y[15,i],t) <-rhosd*nmalL[i]+rhomd*y[14,i]
#ODEs for high -risk males
#Susceptible
D(y[16,i],t) <-chi*nmalH[i]-lambdamalH[i]*y[16,i]-rhosd*y[16,i]
#Infected
D(y[17,i],t) <-lambdamalH[i]*y[16,i]-rhoia*y[17,i]-rhosd*y[17,i]
#Asymptomatic
D(y[18,i],t) <-rhoia*y[17,i]-rhoam*y[18,i]-rhosd*y[18,i]
#Morbid
D(y[19,i],t) <-rhoam*y[18,i]-rhomd*y[19,i]-rhosd*y[19,i]
#Dead
D(y[20,i],t) <-rhosd*nmalH[i]+rhomd*y[19,i]
#number of low -risk females alive
nfemL[i] <- y[1,i]+y[2,i]+y[3,i]+y[4,i]
#number of high -risk females alive
nfemH[i] <- y[6,i]+y[7,i]+y[8,i]+y[9,i]
#number of low -risk males alive
nmalL[i]<-y[11,i]+y[12,i]+y[13,i]+y[14,i]
#number of high -risk males alive
nmalH[i]<-y[16,i]+y[17,i]+y[18,i]+y[19,i]
#probability of selecting a high -risk male partner
gmalH[i] <- (rmalH*nmalH[i])/( rmalH*nmalH[i]+rmalL*nmalL[i])
#probability of selecting a low -risk male partner
gmalL[i] <- 1-gmalH[i]
#probability of selecting a high -risk female partner
gfemH[i] <- (rfemH*nfemH[i])/( rfemH*nfemH[i]+rfemL*nfemL[i])
#probability of selecting a low -risk female partner
gfemL[i] <- 1-gfemH[i]
#prevalence in males
pmal[i] <- gmalH[i]*(y[17,i]/ nmalH[i])+gmalL[i]*(y[12,i]/ nmalL[i])
#prevalence in females
pfem[i] <- gfemH[i]*(y[7,i]/ nfemH[i])+gfemL[i]*(y[2,i]/nfemL[i])
#intervention screening: vaccine coverage (pi2=1), vaccine efficacy (eff2 =0)
#intervention vaccination: vaccine coverage (pi2=pi), vaccine efficacy (eff2=eff)
pi2[i]<-pi*step(i-1.1) +(1-step(i -1.1))
eff2[i]<-eff*step(i-1.1)
#force of infection in the two risk groups and sexes
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lambdafemL[i] <-pi2[i]*(1- eff2[i])*beta*rfemL*pmal[i]+(1-pi2[i])*beta*rfemL*pmal[i]
lambdafemH[i] <-pi2[i]*(1- eff2[i])*beta*rfemH*pmal[i]+(1-pi2[i])*beta*rfemH*pmal[i]
lambdamalL[i] <-pi2[i]*(1- eff2[i])*beta*rmalL*pfem[i]+(1-pi2[i])*beta*rmalL*pfem[i]
lambdamalH[i] <-pi2[i]*(1- eff2[i])*beta*rmalH*pfem[i]+(1-pi2[i])*beta*rmalH*pfem[i]
}
#Initial conditions intervention screening -only:
init [1,1] <- 399760; init [2,1] <- 240; init [3,1] <- 0; init [4,1] <- 0; init [5,1] <- 0;
init [6,1] <- 99940; init [7,1] <- 60; init [8,1] <- 0; init [9,1] <- 0; init [10 ,1] <- 0;
init [11,1] <- 399760; init [12,1] <- 240; init [13,1] <- 0; init [14 ,1] <- 0;
init [15,1] <- 0; init [16,1] <- 99940; init [17 ,1] <- 60; init[18,1]<- 0;
init [19,1] <- 0; init [20,1] <- 0
#initial conditions intervention vaccination are equivalent
init[1,2]<-init [1,1]; init[2,2]<-init [2,1]; init[3,2]<-init [3 ,1]; init[4,2]<-init [4,1];
init[5,2]<-init [5,1]; init[6,2]<-init [6,1]; init[7,2]<-init [7 ,1]; init[8,2]<-init [8,1];
init[9,2]<-init [9,1]; init[10,2]<-init [10 ,1]; init[11,2]<-init [11 ,1];
init[12,2]<-init [12 ,1]; init[13,2]<-init [13 ,1]; init[14,2]<-init [14 ,1];
init[15,2]<-init [15 ,1]; init[16,2]<-init [16 ,1]; init[17,2]<-init [17 ,1];
init[18,2]<-init [18 ,1]; init[19,2]<-init [19 ,1]; init[20,2]<-init [20,1]
#poisson -gamma model on partner acquisition rates
for(i in 1: popsize) {
datfemH[i] ~ dpois(rfemH)
datfemL[i] ~ dpois(rfemL)
datmalH[i] ~ dpois(rmalH)
datmalL[i] ~ dpois(rmalL)
}
#informative priors on partner acquisition rates
rfemH ~ dgamma (0.1 ,0.1)
rfemL ~ dgamma (0.1 ,0.1)
rmalH ~ dgamma (0.1 ,0.1)
rmalL ~ dgamma (0.1 ,0.1)
#informative prior on reproduction rate
chi~dgamma (1111.1 ,111111.1)
#informative prior on transition rate infected --> asymptomatic
rhoia~dgamma (25600 ,32000)
#informative prior on transition rate asymptomatic --> morbid
rhoam~dgamma (2025 ,22500)
#informative prior on transition rate morbid --> dead
rhomd~dgamma (1600 ,40000)
#informative prior on transition rate susceptible --> dead
rhosd~dgamma (156.25 ,312500)
#beta -binomial model on STI transmission probability per partnership. r.beta: number of events , n.beta: sample size
r.beta ~ dbin(beta ,n.beta)
beta ~ dbeta (0.5 ,0.5)
#beta -binomial model on vaccine coverage
r.pi ~ dbin(pi ,n.pi)
pi ~ dbeta (0.5 ,0.5)
#beta -binomial model on vaccine efficacy
r.eff ~ dbin(eff ,n.eff)
eff ~ dbeta (0.5 ,0.5)
#beta -binomial model on probability of diagnosis
r.diag ~ dbin(diag ,n.diag)
diag ~ dbeta (0.5 ,0.5)
#beta -binomial model on probability of screening
r.screen ~ dbin(screen ,n.screen)
screen ~ dbeta (0.5 ,0.5)
#Bayesian model calibration through data on the number of high -risk females and males in the states susceptible ,
infected , asymptomatic and morbid. These are count data and therefore modelled through poisson distributions.
This is done for the first time point of follow -up.
dat.sus.femH [1] ~ dpois(init [6,1])
dat.inf.femH [1] ~ dpois(init [7,1])
dat.asy.femH [1] ~ dpois(init [8,1])
dat.mor.femH [1] ~ dpois(init [9,1])
dat.sus.malH [1] ~ dpois(init [16 ,1])
dat.inf.malH [1] ~ dpois(init [17 ,1])
dat.asy.malH [1] ~ dpois(init [18 ,1])
dat.mor.malH [1] ~ dpois(init [19 ,1])
#Data for time points 2-5 are also available and used to calibrate high -risk people in four of the states. The
constraint (maximum) is included due to a computational issue , is not relevant and can be omitted.
for (n in 2:5){
conssusfemH[n] <- max(0.1, solution[n,6,1])
dat.sus.femH[n] ~ dpois(conssusfemH[n])
consinffemH[n] <- max(0.1, solution[n,7,1])
dat.inf.femH[n] ~ dpois(consinffemH[n])
consasyfemH[n] <- max(0.1, solution[n,8,1])
dat.asy.femH[n] ~ dpois(consasyfemH[n])
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consmorfemH[n] <- max(0.1, solution[n,9,1])
dat.mor.femH[n] ~ dpois(consmorfemH[n])
conssusmalH[n] <- max(0.1, solution[n,16 ,1])
dat.sus.malH[n] ~ dpois(conssusmalH[n])
consinfmalH[n] <- max(0.1, solution[n,17 ,1])
dat.inf.malH[n] ~ dpois(consinfmalH[n])
consasymalH[n] <- max(0.1, solution[n,18 ,1])
dat.asy.malH[n] ~ dpois(consasymalH[n])
consmormalH[n] <- max(0.1, solution[n,19 ,1])
dat.mor.malH[n] ~ dpois(consmormalH[n])
}
#informative priors on costs and utilities
tau.screen <-1/pow (0.693 ,2)
c.screen ~ dlnorm (2.996 , tau.screen)
tau.vac <-1/pow (0.07986607 ,2)
c.vac ~ dlnorm (5.518352 , tau.vac)
tau.test.sti <-1/pow (0.03 ,2)
c.test.sti ~ dlnorm (2.996 , tau.test.sti)
tau.test.blood <-1/pow (0.03 ,2)
c.test.blood ~ dlnorm (3.401 , tau.test.blood)
tau.trt <-1/pow (0.8325546 ,2)
c.trt ~ dlnorm (4.258597 , tau.trt)
tau.trt.dis <-1/pow (0.1980422 ,2)
c.trt.dis ~ dlnorm (6.194998 , tau.trt.dis)
tau.gp <-1/pow (0.02 ,2)
c.gp ~ dlnorm (3.912 , tau.gp)
u.inf ~ dbeta (1469.3 ,629.7)
u.asym ~ dbeta (1439.4 ,959.6)
u.morb ~ dbeta (629.7 ,1469.3)
}
C.2 The Bayesian Markov model
JAGS model
### JAGS model
model {
#y: array including the number of people per year in the states. The first dimension is the year of follow -up , whereas
the second dimension is the state with 1= susceptible low -risk females , 2= infected low -risk females , 3=
asymptomatic low -risk females ,
4= morbid low -risk females , 5=dead low -risk females , 6= susceptible high -risk females ,
7= infected high -risk females , 8= asymptomatic high -risk females , 9= morbid high -risk
females , 10= dead high -risk females , 11= susceptible low -risk males , 12= infected low -
risk males , 13= asymptomatic low -risk males , 14= morbid low -risk males , 15= dead low -
risk males , 16= susceptible high -risk males , 17= infected high -risk males , 18= asympto -
matic high -risk males , 19= morbid high -risk males , 20= dead high -risk males. The third
dimension is the intervention (1= screening , 2= vaccination).
#initialization of states (5 states * 2 sexes * 2 risk groups = 20 entries) for year 1 of follow -up (first dimension of
y)
y[1,1,1] <- 399760; y[1,2,1] <- 240; y[1,3,1] <- 0; y[1,4,1] <- 0; y[1,5,1] <- 0;
y[1,6,1] <- 99940; y[1,7,1] <- 60; y[1,8,1] <- 0; y[1,9,1] <- 0; y[1,10,1] <- 0;
y[1,11,1] <- 399760; y[1,12,1] <- 240; y[1,13,1] <- 0; y[1,14,1] <- 0;
y[1,15,1] <- 0; y[1,16,1] <- 99940; y[1,17,1] <- 60; y[1,18,1] <- 0; y[1,19,1] <- 0;
y[1,20,1] <-0; y[1,1,2] <- y[1,1,1]; y[1,2,2] <- y[1,2,1]; y[1,3,2] <- y[1,3,1];
y[1,4,2] <- y[1,4,1]; y[1,5,2] <- y[1,5,1]; y[1,6,2] <- y[1,6,1]; y[1,7,2] <- y[1,7,1];
y[1,8,2] <- y[1,8,1]; y[1,9,2] <- y[1,9,1]; y[1,10,2] <- y[1 ,10,1];
y[1,11,2] <- y[1,11,1]; y[1,12,2] <- y[1,12,1]; y[1,13,2] <- y[1 ,13,1];
y[1,14,2] <- y[1,14,1]; y[1,15,2] <- y[1,15,1]; y[1,16,2] <- y[1 ,16,1];
y[1,17,2] <- y[1,17,1]; y[1,18,2] <- y[1,18,1]; y[1,19,2] <- y[1 ,19,1];
y[1,20,2] <-y[1 ,20 ,1];
#calculation of sample size according to risk -group and sex for year 1 of follow -up; only those alive are considered
excluding those in the state of death with indices 5, 10, 15, 20)
nfemL [1,1] <- y[1,1,1]+y[1,2,1]+y[1,3,1]+y[1,4,1]
nfemH [1,1] <- y[1,6,1]+y[1,7,1]+y[1,8,1]+y[1,9,1]
nmalL [1,1] <- y[1,11,1]+y[1 ,12,1]+y[1,13 ,1]+y[1,14,1]
nmalH [1,1] <- y[1,16,1]+y[1 ,17,1]+y[1,18 ,1]+y[1,19,1]
nfemL[1,2]<-nfemL [1,1]
nfemH[1,2]<-nfemH [1,1]
nmalL[1,2]<-nmalL [1,1]
nmalH[1,2]<-nmalH [1,1]
#the probabilities of selecting a male/female partner from the high - or low -risk group , respectively , in year 1 of
follow -up
gmalH [1,1] <- (rmalH*nmalH [1 ,1])/( rmalH*nmalH [1 ,1]+ rmalL*nmalL [1 ,1])
gmalL [1,1] <- 1-gmalH [1,1]
gfemH [1,1] <- (rfemH*nfemH [1 ,1])/( rfemH*nfemH [1 ,1]+ rfemL*nfemL [1 ,1])
gfemL [1,1] <- 1-gfemH [1,1]
gmalH[1,2]<-gmalH [1,1]
gmalL[1,2]<-gmalL [1,1]
gfemH[1,2]<-gfemH [1,1]
gfemL[1,2]<-gfemL [1,1]
#weighted average of STI prevalence in males in year 1 of follow -up
pmal [1,1] <- gmalH [1 ,1]*(y[1,17,1]/ nmalH [1 ,1])+gmalL [1 ,1]*(y[1 ,12,1]/ nmalL [1,1])
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#weighted average of STI prevalence in females in year 1 of follow -up
pfem [1,1] <- gfemH [1 ,1]*(y[1,7,1]/ nfemH [1 ,1])+gfemL [1 ,1]*(y[1,2,1]/ nfemL [1 ,1])
pmal[1,2]<-pmal [1,1]
pfem[1,2]<-pfem [1,1]
#force of infection: function of STI transmission probability beta , partner acquisition rates in low -risk females rfemL
(accordingly for the other sex and risk group), and sex -specific population prevalence pmal and pfem , in year 1
of follow -up)
lambdafemL [1,1] <-1-exp(-beta*rfemL*pmal [1,1])
lambdafemH [1,1] <-1-exp(-beta*rfemH*pmal [1,1])
lambdamalL [1,1] <-1-exp(-beta*rmalL*pfem [1,1])
lambdamalH [1,1] <-1-exp(-beta*rmalH*pfem [1,1])
lambdafemL [1,2] <-1-exp(-(pi*(1-eff)*beta*rfemL*pmal [1,2]+(1-pi)*beta*rfemL*pmal [1,2]))
lambdafemH [1,2] <-1-exp(-(pi*(1-eff)*beta*rfemH*pmal [1,2]+(1-pi)*beta*rfemH*pmal [1,2]))
lambdamalL [1,2] <-1-exp(-(pi*(1-eff)*beta*rmalL*pfem [1,2]+(1-pi)*beta*rmalL*pfem [1,2]))
lambdamalH [1,2] <-1-exp(-(pi*(1-eff)*beta*rmalH*pfem [1,2]+(1-pi)*beta*rmalH*pfem [1,2]))
#dat.sus.femH: simulated data on susceptible high -risk females , used for calibration in year 1. The parameter y[1,6,1]
contains the number of susceptible high -risk females in year 1 and is calibrated by the data for year 1. The
approach for high -risk females in the states infected , asymptomatic and morbid as well as for high -risk males in
the same states is conducted accordingly.
dat.sus.femH [1] ~ dpois(y[1,6,1])
dat.inf.femH [1] ~ dpois(y[1,7,1])
dat.asy.femH [1] ~ dpois(y[1,8,1])
dat.mor.femH [1] ~ dpois(y[1,9,1])
dat.sus.malH [1] ~ dpois(y[1,16,1])
dat.inf.malH [1] ~ dpois(y[1,17,1])
dat.asy.malH [1] ~ dpois(y[1,18,1])
dat.mor.malH [1] ~ dpois(y[1,19,1])
#calibration in years 2-5
for(a in 2:5){
dat.sus.femH[a] ~ dpois(max(0.1,y[a,6,1]))
dat.inf.femH[a] ~ dpois(max(0.1,y[a,7,1]))
dat.asy.femH[a] ~ dpois(max(0.1,y[a,8,1]))
dat.mor.femH[a] ~ dpois(max(0.1,y[a,9,1]))
dat.sus.malH[a] ~ dpois(max(0.1,y[a,16 ,1]))
dat.inf.malH[a] ~ dpois(max(0.1,y[a,17 ,1]))
dat.asy.malH[a] ~ dpois(max(0.1,y[a,18 ,1]))
dat.mor.malH[a] ~ dpois(max(0.1,y[a,19 ,1]))
}
for (i in 1:2){
#intervention screening -only: pi2=1, else: pi2=pi
pi2[i]<-ifelse(i==1,1,pi)
#intervention screening -only: eff2=0 (no vaccine efficacy), else: eff2=eff
eff2[i]<-ifelse(i==1,0,eff)
### state allocation algorithm
for (a in 2:A){
#chi is the reproduction rate
#nfemL and lambdafemL are explained above
#pisd is the probability of death from any cause
#piia is the transition probability infection --> asymptomatic
#piam is the transition probability asymptomatic --> morbid
#pimd is the transition probability morbid --> dead
#state allocation of low -risk females in year a; y[a,1,i]= susceptible ,
y[a,2,i]=infected , y[a,3,i]= asymptomatic , y[a,4,i]=morbid , y[a,5,i]=dead
y[a,1,i] <- y[a-1,1,i]+chi*nfemL[a-1,i]-lambdafemL[a-1,i]*y[a-1,1,i]-pisd*y[a-1,1,i]
y[a,2,i] <- y[a-1,2,i]+ lambdafemL[a-1,i]*y[a-1,1,i]-piia*y[a-1,2,i]-pisd*y[a-1,2,i]
y[a,3,i] <- y[a-1,3,i]+piia*y[a-1,2,i]-piam*y[a-1,3,i]-pisd*y[a-1,3,i]
y[a,4,i] <- y[a-1,4,i]+piam*y[a-1,3,i]-pimd*y[a-1,4,i]-pisd*y[a-1,4,i]
y[a,5,i] <- y[a-1,5,i]+pisd*nfemL[a-1,i]+pimd*y[a-1,4,i]
#state allocation of high -risk females in year a; y[a,6,i]= susceptible ,
y[a,7,i]=infected , y[a,8,i]= asymptomatic , y[a,9,i]=morbid , y[a,10,i]=dead
y[a,6,i] <- y[a-1,6,i]+chi*nfemH[a-1,i]-lambdafemH[a-1,i]*y[a-1,6,i]-pisd*y[a-1,6,i]
y[a,7,i] <- y[a-1,7,i]+ lambdafemH[a-1,i]*y[a-1,6,i]-piia*y[a-1,7,i]-pisd*y[a-1,7,i]
y[a,8,i] <- y[a-1,8,i]+piia*y[a-1,7,i]-piam*y[a-1,8,i]-pisd*y[a-1,8,i]
y[a,9,i] <- y[a-1,9,i]+piam*y[a-1,8,i]-pimd*y[a-1,9,i]-pisd*y[a-1,9,i]
y[a,10,i] <- y[a-1,10,i]+pisd*nfemH[a-1,i]+pimd*y[a-1,9,i]
#state allocation of low -risk males in year a; y[a,11,i]= susceptible ,
y[a,12,i]=infected , y[a,13,i]= asymptomatic , y[a,14,i]=morbid , y[a,15,i]=dead
y[a,11,i] <- y[a-1,11,i]+chi*nmalL[a-1,i]-lambdamalL[a-1,i]*y[a-1,11,i]
-pisd*y[a-1,11,i]
y[a,12,i] <- y[a-1,12,i]+ lambdamalL[a-1,i]*y[a-1,11,i]-piia*y[a-1,12,i]
-pisd*y[a-1,12,i]
y[a,13,i] <- y[a-1,13,i]+piia*y[a-1,12,i]-piam*y[a-1,13,i]-pisd*y[a-1,13,i]
y[a,14,i] <- y[a-1,14,i]+piam*y[a-1,13,i]-pimd*y[a-1,14,i]-pisd*y[a-1,14,i]
y[a,15,i] <- y[a-1,15,i]+pisd*nmalL[a-1,i]+pimd*y[a-1,14,i]
#state allocation of high -risk males in year a; y[a,16,i]= susceptible ,
y[a,17,i]=infected , y[a,18,i]= asymptomatic , y[a,19,i]=morbid , y[a,20,i]=dead
y[a,16,i] <- y[a-1,16,i]+chi*nmalH[a-1,i]-lambdamalH[a-1,i]*y[a-1,16,i]
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-pisd*y[a-1,16,i]
y[a,17,i] <- y[a-1,17,i]+ lambdamalH[a-1,i]*y[a-1,16,i]-piia*y[a-1,17,i]
-pisd*y[a-1,17,i]
y[a,18,i] <- y[a-1,18,i]+piia*y[a-1,17,i]-piam*y[a-1,18,i]-pisd*y[a-1,18,i]
y[a,19,i] <- y[a-1,19,i]+piam*y[a-1,18,i]-pimd*y[a-1,19,i]-pisd*y[a-1,19,i]
y[a,20,i] <- y[a-1,20,i]+pisd*nmalH[a-1,i]+pimd*y[a-1,20,i]
#calculation of sample size according to risk group and sex for year a of follow -up; only those alive are
considered excluding those in the state of death (with indices 5, 10, 15, 20)
nfemL[a,i] <- y[a,1,i]+y[a,2,i]+y[a,3,i]+y[a,4,i]
nfemH[a,i] <- y[a,6,i]+y[a,7,i]+y[a,8,i]+y[a,9,i]
nmalL[a,i] <- y[a,11,i]+y[a,12,i]+y[a,13,i]+y[a,14,i]
nmalH[a,i] <- y[a,16,i]+y[a,17,i]+y[a,18,i]+y[a,19,i]
#the probabilities of selecting a male/female partner from the high - or low -risk group , respectively , in year a of
follow -up
gmalH[a,i] <- (rmalH*nmalH[a,i])/(rmalH*nmalH[a,i]+ rmalL*nmalL[a,i])
gmalL[a,i] <- 1-gmalH[a,i]
gfemH[a,i] <- (rfemH*nfemH[a,i])/(rfemH*nfemH[a,i]+ rfemL*nfemL[a,i])
gfemL[a,i] <- 1-gfemH[a,i]
#weighted average of STI prevalence in males in year a of follow -up
pmal[a,i] <- gmalH[a,i]*(y[a,17,i]/nmalH[a,i])+gmalL[a,i]*(y[a,12,i]/ nmalL[a,i])
#weighted average of STI prevalence in females in year a of follow -up
pfem[a,i] <- gfemH[a,i]*(y[a,7,i]/nfemH[a,i])+gfemL[a,i]*(y[a,2,i]/nfemL[a,i])
#force of infection: function of STI transmission probability beta , partner acquisition rates in low -risk females
rfemL (accordingly for the other sex and risk group), and sex -specific population prevalence pmal and pfem ,
in year a of follow -up)
lambdafemL[a,i] <-1-exp(-(pi2[i]*(1- eff2[i])*beta*rfemL*pmal[a,i]+(1-pi2[i])*beta
*rfemL*pmal[a,i]))
lambdafemH[a,i] <-1-exp(-(pi2[i]*(1- eff2[i])*beta*rfemH*pmal[a,i]+(1-pi2[i])*beta
*rfemH*pmal[a,i]))
lambdamalL[a,i] <-1-exp(-(pi2[i]*(1- eff2[i])*beta*rmalL*pfem[a,i]+(1-pi2[i])*beta
*rmalL*pfem[a,i]))
lambdamalH[a,i] <-1-exp(-(pi2[i]*(1- eff2[i])*beta*rmalH*pfem[a,i]+(1-pi2[i])*beta
*rmalH*pfem[a,i]))
}
}
#poisson -gamma model to update informative priors on partner acquisition rates by data
#datfemH: number of yearly partners in high -risk females , accordingly for the other sex and risk group
#rfemH: partner acquisition rate in high -risk females , accordingly for the other sex and risk group
#popsize: population size of the simulated data on yearly partners; we assume that 500 individuals were interviewed on
their yearly number of partners
for(i in 1: popsize){
datfemH[i] ~ dpois(rfemH)
datfemL[i] ~ dpois(rfemL)
datmalH[i] ~ dpois(rmalH)
datmalL[i] ~ dpois(rmalL)
}
#informative priors on partner acquisition rates
rfemH ~ dgamma (0.1 ,0.1)
rfemL ~ dgamma (0.1 ,0.1)
rmalH ~ dgamma (0.1 ,0.1)
rmalL ~ dgamma (0.1 ,0.1)
#informative prior on reproduction rate chi.
chi~dgamma (1111.1 ,111111.1)
#informative prior on transition probability infected --> asymptomatic
piia~dbeta (5119.2 , 1279.8)
#informative prior on transition probability asymptomatic --> morbid
piam~dbeta (1842.66 ,18631.34)
#informative prior on transition probability morbid --> dead
pimd~dbeta (1535.96 ,36863.04)
#informative prior on transition probability susceptible --> dead
pisd~dbeta (156.1714 ,312186.6)
#beta -binomial model on probability STI transmission. r.beta: number of events , n.beta: sample size
r.beta ~ dbin(beta ,n.beta)
#minimally -informative prior on beta
beta ~ dbeta (0.5 ,0.5)
#beta -binomial model on probability of diagnosis. r.diag: number of events , n.diag: sample size
r.diag ~ dbin(diag ,n.diag)
#minimally -informative prior on diag
diag ~ dbeta (0.5 ,0.5)
#beta -binomial model on probability of screening. r.screen: number of events , n.screen: sample size
r.screen ~ dbin(screen ,n.screen)
#minimally -informative prior on screen
screen ~ dbeta (0.5 ,0.5)
#beta -binomial model on vaccine coverage. r.pi: number of events , n.pi: sample size
r.pi ~ dbin(pi ,n.pi)
#minimally -informative prior on pi
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pi ~ dbeta (0.5 ,0.5)
#beta -binomial model on vaccine efficacy. r.eff: number of events , n.eff: sample size
r.eff ~ dbin(eff ,n.eff)
#minimally -informative prior on eff
eff ~ dbeta (0.5 ,0.5)
#informative priors on costs and utilities
tau.screen <-1/pow (0.693 ,2)
c.screen ~ dlnorm (2.996 , tau.screen)
tau.vac <-1/pow (0.07986607 ,2)
c.vac ~ dlnorm (5.518352 , tau.vac)
tau.test.sti <-1/pow (0.03 ,2)
c.test.sti ~ dlnorm (2.996 , tau.test.sti)
tau.test.blood <-1/pow (0.03 ,2)
c.test.blood ~ dlnorm (3.401 , tau.test.blood)
tau.trt <-1/pow (0.8325546 ,2)
c.trt ~ dlnorm (4.258597 , tau.trt)
tau.trt.dis <-1/pow (0.1980422 ,2)
c.trt.dis ~ dlnorm (6.194998 , tau.trt.dis)
tau.gp <-1/pow (0.02 ,2)
c.gp ~ dlnorm (3.912 , tau.gp)
#utility of infected
u.inf ~ dbeta (1469.3 ,629.7)
#utility of asymptomatic
u.asym ~ dbeta (1439.4 ,959.6)
#utility of morbid
u.morb ~ dbeta (629.7 ,1469.3)}
WinBUGS model
### WinBUGS model
model {
#initialization
female [1,1,1,1] <- 399760; female [1,1,1,2] <- 240; female [1,1,1,3] <- 0;
female [1,1,1,4] <- 0; female [1,1,1,5] <- 0; female [1,2,1,1] <- 99940;
female [1,2,1,2] <- 60; female [1,2,1,3] <- 0; female [1,2,1,4] <- 0;
female [1,2,1,5] <- 0;
male[1,1,1,1] <- 399760; male[1,1,1,2] <- 240; male[1,1,1,3] <- 0;
male[1,1,1,4] <- 0; male[1,1,1,5] <- 0; male[1,2,1,1] <- 99940;
male[1,2,1,2] <- 60; male[1,2,1,3] <- 0; male[1,2,1,4] <- 0;
male[1,2,1,5] <- 0;
female [1,1,2,1] <- 399760; female [1,1,2,2] <- 240; female [1,1,2,3] <- 0;
female [1,1,2,4] <- 0; female [1,1,2,5] <- 0; female [1,2,2,1] <- 99940;
female [1,2,2,2] <- 60; female [1,2,2,3] <- 0; female [1,2,2,4] <- 0;
female [1,2,2,5] <- 0;
male[1,1,2,1] <- 399760; male[1,1,2,2] <- 240; male[1,1,2,3] <- 0;
male[1,1,2,4] <- 0; male[1,1,2,5] <- 0; male[1,2,2,1] <- 99940;
male[1,2,2,2] <- 60; male[1,2,2,3] <- 0; male[1,2,2,4] <- 0;
male[1,2,2,5] <- 0;
#calculation of sample size according to risk -group and sex for year 1 of follow -up; only those alive are considered
#excluding those in the state of death with indices 5, 10, 15, 20)
nfem[1,1,1] <- female [1,1,1,1]+ female [1,1,1,2]+ female [1,1,1,3]+ female [1,1,1,4]
nmal[1,1,1] <- male [1,1,1,1]+ male [1,1,1,2]+ male [1,1,1,3]+ male[1,1,1,4]
nfem[1,2,1] <- female [1,2,1,1]+ female [1,2,1,2]+ female [1,2,1,3]+ female [1,2,1,4]
nmal[1,2,1] <- male [1,2,1,1]+ male [1,2,1,2]+ male [1,2,1,3]+ male[1,2,1,4]
nfem[1,1,2]<-nfem [1,1,1]
nmal[1,1,2]<-nmal [1,1,1]
nfem[1,2,2]<-nfem [1,2,1]
nmal[1,2,2]<-nmal [1,2,1]
#the probabilities of selecting a male/female partner from the high - or low -risk group , respectively , in year 1 of
follow -up
gmalH [1,1] <- (rmalH*nmal [1,2,1])/(rmalH*nmal [1,2,1]+ rmalL*nmal [1,1,1])
gmalL [1,1] <- 1-gmalH [1,1]
gfemH [1,1] <- (rfemH*nfem [1,2,1])/(rfemH*nfem [1,2,1]+ rfemL*nfem [1,1,1])
gfemL [1,1] <- 1-gfemH [1,1]
gmalH[1,2]<-gmalH [1,1]
gmalL[1,2]<-gmalL [1,1]
gfemH[1,2]<-gfemH [1,1]
gfemL[1,2]<-gfemL [1,1]
#calibration
dat.sus.femH [1] ~ dpois(female [1,2,1,1])
dat.inf.femH [1] ~ dpois(female [1,2,1,2])
dat.asy.femH [1] ~ dpois(female [1,2,1,3])
dat.mor.femH [1] ~ dpois(female [1,2,1,4])
dat.sus.malH [1] ~ dpois(male [1,2,1,1])
dat.inf.malH [1] ~ dpois(male [1,2,1,2])
dat.asy.malH [1] ~ dpois(male [1,2,1,3])
dat.mor.malH [1] ~ dpois(male [1,2,1,4])
#dat.sus.femH: simulated data on susceptible high -risk females , used for calibration in year 1. The parameter female[n
,2,1,1] contains the number of susceptible high -risk females in year 1 and is calibrated by the data for year 1.
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The approach for high -risk females in the states infected , asymptomatic and morbid as well as for high -risk males
in the same states is conducted accordingly.
for (n in 2:5){
conssusfemH[n] <- max(0.1, female[n,2,1,1])
dat.sus.femH[n] ~ dpois(conssusfemH[n])
consinffemH[n] <- max(0.1, female[n,2,1,2])
dat.inf.femH[n] ~ dpois(consinffemH[n])
consasyfemH[n] <- max(0.1, female[n,2,1,3])
dat.asy.femH[n] ~ dpois(consasyfemH[n])
consmorfemH[n] <- max(0.1, female[n,2,1,4])
dat.mor.femH[n] ~ dpois(consmorfemH[n])
conssusmalH[n] <- max(0.1, male[n,2,1,1])
dat.sus.malH[n] ~ dpois(conssusmalH[n])
consinfmalH[n] <- max(0.1, male[n,2,1,2])
dat.inf.malH[n] ~ dpois(consinfmalH[n])
consasymalH[n] <- max(0.1, male[n,2,1,3])
dat.asy.malH[n] ~ dpois(consasymalH[n])
consmormalH[n] <- max(0.1, male[n,2,1,4])
dat.mor.malH[n] ~ dpois(consmormalH[n])
}
#state allocation algorithm for years 2-5 of follow -up
#year a
for (a in 1:A){
#sexual behaviour group g (1=low -risk , 2=high -risk)
for (g in 1:2){
#intervention i (1= screening -only , 2= vaccination)
for (i in 1:2){
#transition probability matrix. Lambda: transition probabilities in females , Kappa: transition probabilties in
males
Lambda[a,g,i,1,3]<-0
Lambda[a,g,i,1,4]<-0
Lambda[a,g,i,1,5]<-pisd
Lambda[a,g,i,2,1]<-0
Lambda[a,g,i,2,2]<-1-piia -pisd
Lambda[a,g,i,2,3]<-piia
Lambda[a,g,i,2,4]<-0
Lambda[a,g,i,2,5]<-pisd
Lambda[a,g,i,3,1]<-0
Lambda[a,g,i,3,2]<-0
Lambda[a,g,i,3,3]<-1-piam -pisd
Lambda[a,g,i,3,4]<-piam
Lambda[a,g,i,3,5]<-pisd
Lambda[a,g,i,4,1]<-0
Lambda[a,g,i,4,2]<-0
Lambda[a,g,i,4,3]<-0
Lambda[a,g,i,4,4]<-1-pisd -pimd
Lambda[a,g,i,4,5]<-pisd+pimd
Lambda[a,g,i,5,1]<-0
Lambda[a,g,i,5,2]<-0
Lambda[a,g,i,5,3]<-0
Lambda[a,g,i,5,4]<-0
Lambda[a,g,i,5,5]<-1
Kappa[a,g,i,1,3]<-0
Kappa[a,g,i,1,4]<-0
Kappa[a,g,i,1,5]<-pisd
Kappa[a,g,i,2,1]<-0
Kappa[a,g,i,2,2]<-1-piia -pisd
Kappa[a,g,i,2,3]<-piia
Kappa[a,g,i,2,4]<-0
Kappa[a,g,i,2,5]<-pisd
Kappa[a,g,i,3,1]<-0
Kappa[a,g,i,3,2]<-0
Kappa[a,g,i,3,3]<-1-piam -pisd
Kappa[a,g,i,3,4]<-piam
Kappa[a,g,i,3,5]<-pisd
Kappa[a,g,i,4,1]<-0
Kappa[a,g,i,4,2]<-0
Kappa[a,g,i,4,3]<-0
Kappa[a,g,i,4,4]<-1-pisd -pimd
Kappa[a,g,i,4,5]<-pisd+pimd
Kappa[a,g,i,5,1]<-0
Kappa[a,g,i,5,2]<-0
Kappa[a,g,i,5,3]<-0
Kappa[a,g,i,5,4]<-0
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Kappa[a,g,i,5,5]<-1
}
}
}
for (i in 1:2){
#vaccine coverage and efficacy per intervention i
pi2[i]<-pi*step(i-1.1) +(1-step(i -1.1))
eff2[i]<-eff*step(i-1.1)
for (a in 2:A){
#weighted average of STI prevalence in males and females in year a of follow -up
pmal[a,i] <- gmalH[a-1,i]*( male[a-1,2,i,2]/ nmal[a-1,2,i])+gmalL[a-1,i]
*(male[a-1,1,i,2]/ nmal[a-1,1,i])
pfem[a,i] <- gfemH[a-1,i]*( female[a-1,2,i,2]/ nfem[a-1,2,i])+gfemL[a-1,i]
*( female[a-1,1,i,2]/ nfem[a-1,1,i])
#force of infection and probability of remaining susceptible
Lambda[a,1,i,1,2]<-1-exp(-(pi2[i]*(1- eff2[i])*beta*rfemL*pmal[a,i]+(1-pi2[i])*beta
*rfemL*pmal[a,i]))
Lambda[a,1,i,1,1]<-1-Lambda[a,1,i,1,2]-pisd
Lambda[a,2,i,1,2]<-1-exp(-(pi2[i]*(1- eff2[i])*beta*rfemH*pmal[a,i]+(1-pi2[i])*beta
*rfemH*pmal[a,i]))
Lambda[a,2,i,1,1]<-1-Lambda[a,2,i,1,2]- Lambda[a,2,i,1,5]
Kappa[a,1,i,1,2]<-1-exp(-(pi2[i]*(1- eff2[i])*beta*rmalL*pfem[a,i]+(1-pi2[i])*beta
*rmalL*pfem[a,i]))
Kappa[a,1,i,1,1]<-1-Kappa[a,1,i,1,2]-Kappa[a,1,i,1,5]
Kappa[a,2,i,1,2]<-1-exp(-(pi2[i]*(1- eff2[i])*beta*rmalH*pfem[a,i]+(1-pi2[i])*beta
*rmalH*pfem[a,i]))
Kappa[a,2,i,1,1]<-1-Kappa[a,2,i,1,2]-Kappa[a,2,i,1,5]
#state allocation algorithm
for (g in 1:2){
#accounting for proliferation in population
female[a,g,i,1] <-(inprod(female[a-1,g,i,], Lambda[a,g,i,,1]))+chi*nfem[a-1,g,i]
male[a,g,i,1] <-(inprod(male[a-1,g,i,], Kappa[a,g,i,,1]))+chi*nmal[a-1,g,i]
#inner product of number of people in states and transition probability matrices
for (s in 2:5){
female[a,g,i,s] <-inprod(female[a-1,g,i,], Lambda[a,g,i,,s])
male[a,g,i,s] <-inprod(male[a-1,g,i,], Kappa[a,g,i,,s])
}
#calculating sample size of females and males
nfem[a,g,i] <- female[a,g,i,1]+ female[a,g,i,2]+ female[a,g,i,3]+ female[a,g,i,4]
nmal[a,g,i] <- male[a,g,i,1]+ male[a,g,i,2]+ male[a,g,i,3]+ male[a,g,i,4]
}
#calculating probabilities of selecting partners from the two risk groups
gmalH[a,i] <- (rmalH*nmal[a,2,i])/( rmalH*nmal[a,2,i]+rmalL*nmal[a,1,i])
gmalL[a,i] <- 1-gmalH[a,i]
gfemH[a,i] <- (rfemH*nfem[a,2,i])/( rfemH*nfem[a,2,i]+rfemL*nfem[a,1,i])
gfemL[a,i] <- 1-gfemH[a,i]
}
}
#poisson -gamma model to update informative priors on partner acquisition rates by data
#datfemH: number of yearly partners in high -risk females , accordingly for the other sex and risk -group
#rfemH: partner acquisition rate in high -risk females , accordingly for the other sex and risk -group
#popsize: population size of the simulated data on yearly partners; we assume that 500 individuals were interviewed on
their yearly number of partners
for(i in 1: popsize){
datfemH[i] ~ dpois(rfemH)
datfemL[i] ~ dpois(rfemL)
datmalH[i] ~ dpois(rmalH)
datmalL[i] ~ dpois(rmalL)
}
#informative priors on partner acquisition rates
rfemH ~ dgamma (0.1 ,0.1)
rfemL ~ dgamma (0.1 ,0.1)
rmalH ~ dgamma (0.1 ,0.1)
rmalL ~ dgamma (0.1 ,0.1)
#informative prior on reproduction rate chi
chi~dgamma (1111.1 ,111111.1)
#informative prior on transition probability infected --> asymptomatic
piia~dbeta (5119.2 , 1279.8)
#informative prior on transition probability asymptomatic --> morbid
piam~dbeta (1842.66 ,18631.34)
#informative prior on transition probability morbid --> dead
pimd~dbeta (1535.96 ,36863.04)
#informative prior on transition probability susceptible --> dead
pisd~dbeta (156.1714 ,312186.6)
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#beta -binomial model on probability STI transmission. r.beta: number of events , n.beta: sample size
r.beta ~ dbin(beta ,n.beta)
#minimally -informative prior on beta
beta ~ dbeta (0.5 ,0.5)
#beta ~dbeta (764.85 ,4334.15)
#beta -binomial model on probability of diagnosis. r.diag: number of events , n.diag: sample size
r.diag ~ dbin(diag ,n.diag)
#minimally -informative prior on diag
diag ~ dbeta (0.5 ,0.5)
#beta -binomial model on probability of screening. r.screen: number of events , n.screen: sample size
r.screen ~ dbin(screen ,n.screen)
#minimally -informative prior on screen
screen ~ dbeta (0.5 ,0.5)
#beta - binomial model on vaccine coverage
r.pi ~ dbin(pi ,n.pi)
pi ~ dbeta (0.5 ,0.5)
#beta - binomial model on vaccine efficacy
r.eff ~ dbin(eff ,n.eff)
eff ~ dbeta (0.5 ,0.5)
#costs and utilities
tau.screen <-1/pow (0.693 ,2)
c.screen ~ dlnorm (2.996 , tau.screen)
tau.vac <-1/pow (0.07986607 ,2)
c.vac ~ dlnorm (5.518352 , tau.vac)
tau.test.sti <-1/pow (0.03 ,2)
c.test.sti ~ dlnorm (2.996 , tau.test.sti)
tau.test.blood <-1/pow (0.03 ,2)
c.test.blood ~ dlnorm (3.401 , tau.test.blood)
tau.trt <-1/pow (0.8325546 ,2)
c.trt ~ dlnorm (4.258597 , tau.trt)
tau.trt.dis <-1/pow (0.1980422 ,2)
c.trt.dis ~ dlnorm (6.194998 , tau.trt.dis)
tau.gp <-1/pow (0.02 ,2)
c.gp ~ dlnorm (3.912 , tau.gp)
#utility of infected
u.inf ~ dbeta (1469.3 ,629.7)
#utility of asymptomatic
u.asym ~ dbeta (1439.4 ,959.6)
#utility of morbid
u.morb ~ dbeta (629.7 ,1469.3)
}
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